Search Results

FDA

FDA Clears DyAnsys Neurostimulation Device Primary Relief to Treat Post-Cardiac Surgery Pain

DyAnsys, Inc., has announced that Primary Relief, a percutaneous electrical neurostimulation device, has been approved to treat pain following a cardiac surgery.

September 22, 2022

·

2 min read

Biotech Bay

FDA Clears DyAnsys Neurostimulation Device Primary Relief to Treat C-Section Pain

DyAnsys, Inc., has announced that Primary Relief, a percutaneous electrical neurostimulation device, has been clearedto treat pain following a Caesarean-section (C-section).

July 28, 2022

·

2 min read

FDA

FDA Clears DyAnsys Neurostimulation Device First Relief to treat Diabetic Neuropathic Pain

First Relief, a PENS (percutaneous electrical neurostimulation) device, has been cleared by the US Food and Drug Administration for multiple treatments up to 56 days for symptomatic relief of chronic, intractable pain from diabetic peripheral neuropathy, Dyansys Inc. has announced.

July 14, 2022

·

2 min read

FDA

U.S. Food and Drug Administration Clears Wearable Device to Treat Opioid Addiction

DyAnsys Inc. announced that the U.S. Food and Drug Administration has cleared its auricular neurostimulation device, Drug Relief®, to be used as an aid to reduce the symptoms of opioid withdrawal without narcotics.

June 12, 2018

·

2 min read

Biotech Bay

New DyAnsys Solution Relieves Long-term Chronic Pain Without Narcotics

May 19, 2015

·

2 min read